Influence of rifampin on serum markers of cholesterol and bile acid synthesis in men
The DOI matches its Crossref record.
Abstract
OBJECTIVE: It has been demonstrated in preliminary studies that rifampin, a semisynthetic antibiotic and known inducer of hepatic cytochrome P450 3A4, reduces serum concentrations of total bile acids only in individuals with liver disease and elevated serum bile acid levels. METHODS: We studied the effect of rifampin on concentrations of surrogate serum markers of cholesterol and bile acid synthesis as well as of cholesterol absorption in 10 male subjects before and after administration of rifampin (600 mg/day) for 6 days. Cholesterol and its precursors were analyzed by gas-liquid chromatography (GLC), bile acid intermediates and individual bile acids by isotope-dilution methods using GLC-mass spectrometry (MS) or by high-performance liquid chromatography (HPLC). RESULTS: Treatment with rifampin resulted in a 70% increase (p = 0.008) of the serum concentration of the bile acid precursor 7alpha-hydroxy-4-cholesten-3-one, which is a marker for bile acid production. Serum total cholesterol was not altered, however, treatment with rifampin elevated the ratio of lathosterol to cholesterol, an indicator of cholesterol synthesis, by 23% (p = 0.037). Interestingly, serum concentration of total bile acids decreased slightly by 29% (p = 0.022), mainly due to a lowering of the secondary bile acid, deoxycholic acid (-60%; p = 0.005). CONCLUSION: A 6-day treatment with rifampin induces a reduction of deoxycholic serum concentrations in healthy men associated with a moderate increase of serum markers of bile acid and endogenous cholesterol synthesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Defective cholesterol clearance limits remyelination in the aged central nervous system
Cantuti-Castelvetri, L., Fitzner, D., Bosch-Queralt, M., Weil, M.-T., Su, M., Sen, P., Ruhwedel, T., Mitkovski, M., Trendelenburg, G., Lütjohann, D., et al. (2018) · Science · doi:10.1126/science.aan4183 · Cited by 586
Self-citationCyclodextrin promotes atherosclerosis regression via macrophage reprogramming
Zimmer, S., Grebe, A., Bakke, S. S., Bode, N., Halvorsen, B., Ulas, T., Skjelland, M., De Nardo, D., Labzin, L. I., Kerksiek, A., et al. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad6100 · Cited by 360
Self-citationZollner, G., Marschall, H.-U., Wagner, M., & Trauner, M. (2006) · Molecular Pharmaceutics · doi:10.1021/mp060010s · Cited by 335
MARSCHALL, H., WAGNER, M., ZOLLNER, G., FICKERT, P., DICZFALUSY, U., GUMHOLD, J., SILBERT, D., FUCHSBICHLER, A., BENTHIN, L., & GRUNDSTROM, R. (2005) · Gastroenterology · doi:10.1016/j.gastro.2005.05.009 · Cited by 325
Nuclear receptors as therapeutic targets in cholestatic liver diseases
Zollner, G., & Trauner, M. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2008.00030.x · Cited by 146
“However, in vivo administration of the PXR ligand rifampicin did not significantly reduce CYP7A1 expression or bile acid synthesis in humans (Lutjohann et al., 2004; Marschall et al., 2005) questioning the physiologic significance of PXR-mediated repression.”
Segovia-Miranda, F., Morales-Navarrete, H., Kücken, M., Moser, V., Seifert, S., Repnik, U., Rost, F., Brosch, M., Hendricks, A., Hinz, S., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0660-7 · Cited by 109
Self-citation
Metadata
- Authors
- Lütjohann, D., Hahn, C., Prange, W., Sudhop, T., Axelson, M., Sauerbruch, T., Bergmann, K. V., & Reichel, C.
- Venue
- Int. Journal of Clinical Pharmacology and Therapeutics
- Publisher
- Dustri-Verlgag Dr. Karl Feistle
- Published
- 2004-06-01
- Volume
- 42
- Issue
- 06
- Pages
- 307-313
- ISSN
- 0946-1965 (ISSN-L)
- OpenAlex
- W2063697432
- Cited by
- 39
- References
- 0
- FWCI
- 1.51
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.